Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Natan Ponieman

MindMed Shares Soar After FDA Approves First Commercial Clinical Trial On LSD In 40 Years

MindMed (NASDAQ:MNMD), a drug development company in the psychedelics space, announced on Tuesday that the FDA has allowed an investigational new drug application for a Phase 2b trial on a proprietary LSD analog.

Shares from the company peaked at $1.30 and closed the Tuesday trading session at $1.17, marking a 25% increase from the previous day.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.